The ophthalmic viscosurgical device (OVD) is a clear, viscous protective gel formula injected into a patient’s eye to protect and coat the eye during surgery, reducing trauma to the inside layer of the cornea and other surrounding tissues.
Abbott says the surgical delivery system for its latest OVD includes a number of features for increased patient safety and ease of handling for the surgeon, including a smaller delivery device and improved ergonomics for a smooth and consistent delivery of the formula to the eye.
The new OVD received Australian Therapeutic Goods Administration (TGA) approval in June. US Food and Drug Administration followed in July. Abbott Optical Australia says the device was placed on the Australian Prostheses Benefit List in August.
Promote the message that 75 per cent of blindness and vision loss is preventable or treatable
Professor Roger Steinert, the Director of the Gavin Herbert Eye Institute at the University of California, says a “dispersive OVD is highly desirable at the beginning of the cataract removal process to help protect the eye from nuclear particles and ultrasonic energy”.
“Healon EndoCoat OVD is ideal for this protective barrier. It has outstanding clarity and does not require refrigeration, which reduces storage costs and improves ease of use compared to a cold syringe.”
